Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > COVID-19: ANSM wishes to suspend clinical trials evaluating hydroxychloroquine treatment in patients as a precaution – Information Point

The ANSM was informed of the position of the scientific committee of the international Solidarity clinical trial in collaboration with the WHO on the suspension of the inclusions of new patients who had to be treated with hydroxychloroquine

Philippe Calandra 29 May 2020 All news
  • ← Amendment to Implementing Regulation 920/2013 on the designation of notified bodies
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 January 2021
  • EMA – Questions & answers on signal management
  • PRAC recommendations on signals
Copyright © 2018 - Pharmya - Legal terms - Quality Policy